Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CanAssist
Bangalore, Karnataka, India
- Ownership
- Private
- Development stage
- Other
01
Overview
CanAssist Breast (CAB) is a prognostic diagnostic test for early-stage hormone-positive, HER2-negative breast cancer, predicting 5-year recurrence risk with high negative predictive value (NPV >95%). It combines IHC-based protein expression of 5 biomarkers (CD44, Pan-Cadherin, N-Cadherin, ABCC4, ABCC11) with clinical parameters (tumor size, node status, grade) via AI algorithm, launched in 2016.[1][2][6]
- Therapeutic areas
- Oncology
- Modalities
- Diagnostic test
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
Sapien BiosciencesApollo Hospitals
Beyond the preview
Go deeper on CanAssist.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CanAssist.